Mumbai, Dec. 16 -- Apnar Pharma is a pharmaceutical company primarily engaged in the business of manufacture of generic pharmaceutical formulations, having US FDA, UK-MHRA and Health Canada approved manufacturing facility near Vadodara, Gujarat. Its turnover was Rs 14.21 crore in FY25.

The acquisition will be completed in two tranches, with a first tranche involving the acquisition of 75% stake, expected to be completed in current fiscal by March 2026. The remaining 25% stake is expected to be completed by Q2 of FY 2027.

The company will acquire entire stake at total enterprise value of approximately Rs 91 crore. Of this, around Rs 76 crore represents debt and assumed liabilities related to the manufacturing facility, while the balance ...